Evidence map›Paper›PMID 30690787›Full record

ArticleJournal of leukocyte biology2019

Frontline Science: Employing enzymatic treatment options for management of ocular biofilm-based infections.

Abirami Kugadas, Jennifer Geddes-McAlister, Emilia Guy, Antonio DiGiandomenico, David B Sykes, Michael K Mansour, Rossen Mirchev, Mihaela Gadjeva

Open access · bronzeAbstract read
In one paragraph

Article in Journal of leukocyte biology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
3.5field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 24 citations in OpenAlex.

  1. Review
  2. Remodeling of the neutrophil proteome upon exposure toMicrobiology resource announcements · 2025
    Article
  3. iScience · 2025
    Article
  4. Article
  5. Visualisation of Host-Pathogen Communication.Advances in experimental medicine and biology · 2023
    Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Pathogenesis of Fungal and Bacterial Microbes.Pathogens (Basel, Switzerland) · 2020
    Article
  11. Article
  12. Review
  13. Review
  14. Article
  15. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 2 countries.

Abirami KugadasDepartment of Medicine, Division of Infectious Diseases, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Jennifer Geddes-McAlisterProteomics and Signal Transduction Department, Max Planck Institute of Biochemistry, Martinsried, Germany.
Emilia GuyDepartment of Medicine, Division of Infectious Diseases, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Antonio DiGiandomenicoMedImmune, LLC, Gaithersburg, Maryland, USA.
David B SykesCenter for Regenerative Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA.
Michael K MansourDivision of Infectious Diseases, Massachusetts General Hospital, Boston, Massachusetts, USA.
Rossen MirchevBiological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts, USA.
Mihaela GadjevaDepartment of Medicine, Division of Infectious Diseases, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Brigham and Women's Hospital · USHarvard University · USMassachusetts General Hospital · USMax Planck Institute of Biochemistry · DE

Funding

Novel treatment strategies to regulate inflammation during P.aeruginosa keratitisR01EY022054 · NEI · BRIGHAM AND WOMEN'S HOSPITAL · PI GADJEVA, MIHAELA GUEORGUIEVA · 2012 to 2020
$4.0M
NEI NIH HHS R01 EY022054
6 · The paper itself

Abstract

Pseudomonas aeruginosa-induced corneal keratitis is a sight-threatening disease. The rise of antibiotic resistance among P. aeruginosa keratitis isolates makes treatment of this disease challenging, emphasizing the need for alternative therapeutic modalities. By comparing the responses to P. aeruginosa infection between an outbred mouse strain (Swiss Webster, SW) and a susceptible mouse strain (C57BL6/N), we found that the inherent neutrophil-killing abilities of these strains correlated with their susceptibility to infection. Namely, SW-derived neutrophils were significantly more efficient at killing P. aeruginosa in vitro than C57BL6/N-derived neutrophils. To interrogate whether the distinct neutrophil killing capacities were dependent on endogenous or exogenous factors, neutrophil progenitor cell lines were generated. The in vitro differentiated neutrophils from either SW or C57BL6/N progenitors retained the differential killing abilities, illustrating that endogenous factors conferred resistance. Consistently, quantitative LC-MS/MS analysis revealed strain-specific and infection-induced alterations of neutrophil proteomes. Among the distinctly elevated proteins in the SW-derived proteomes were α-mannosidases, potentially associated with protection. Inhibition of α-mannosidases reduced neutrophil bactericidal functions in vitro. Conversely, topical application of α-mannosidases reduced bacterial biofilms and burden of infected corneas. Cumulatively, these data suggest novel therapeutic approaches to control bacterial biofilm assembly and improve bacterial clearance via enzymatic treatments.

Indexed as

CorneaAnimalsBiofilmsEye Infections, BacterialMiceNeutrophilsPseudomonas aeruginosaPseudomonas InfectionsSpecies Specificitybiofilmsinnate immunityneutrophilsP. aeruginosa

Identifiers

PMID30690787
PMCPMC6618031
OpenAlexW2920780191

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.